Interestingly, both reports agreed that Group 3 MB tumours with MYC amplification or overexpression have a dismal outcome and the poorest prognosis, highlighting that it is of a paramount importance to tailor MB treatments to its biology. This evidence concerns the gene MYC and neoplasm.